Amniox Medical today released results from a clinical study of its Clarix cryopreserved amniotic membrane in lumbar microdiscectomy surgeries, touting freedom from re-herniation for 2-years. Results from the trial were published in the May 2017 issue of Clinical Spine Surgery, the Atlanta-based company said. In the 80-person study, researchers compared the use of the Clarix 100 […]
Amniox Medical said yesterday it landed a Federal Supply Schedule contract for its Neox and Clarix regenerative product lines with the US Military Health System. The Neox wound allograft is designed for use as a wound covering for dermal ulcers and defects, while its Clarix regenerative matrix is indicated for use as a surgical covering, wrap […]
Amniox Medical this month touted a reimbursement win from Palmetto Medicare as well as a 2-year cryopreserved lifespan for its Neox Cord 1k as it attempts to position itself as a market leader in wound care. The Atlanta, Ga.-based company said that Palmetto Medicare recently included Amniox’s Neox Cord 1k and Neox 100 would allografts […]
Amniox Medical said yesterday it won reimbursement for its Neox wound matrix umbilical cord allograft through Wisconsin Physicians Service Insurance corp, who will provide Medicare coverage for the treatment for chronic, non-healing wounds. The WPS Insurance group administers Part A and Part B Medicare benefits for Iowa, Kansas, Missouri, Nebraska, Indiana and Michigan for 4.4 million individuals, […]
Amniox Medical today released results from a retrospective study of its Neox wound allograft in treating chronic diabetic foot ulcers touting an 87% rate of healing in patients treated with the allograft. Findings from the study were presented at Superbones Superwounds East 2016 in Teanack, N.J. last week. “These findings are quite positive for the […]
TissueTech said today that it added another $15 million to its coffers, led by prior backers River Cities Capital Funds and Ballast Point Ventures. Doral, Fla.-based TissueTech makes amniotic membrane- and umbilical cord-based products designed to treat ocular surface diseases (its Bio-Tissue subsidiary) and musculoskeletal conditions and wound care (its Amniox Medical business). The company raised […]
TissueTech Inc. said it pulled down $10 million from a pair of venture capital shops to back its regenerative medicine subsidiaries, Bio-Tissue and Amniox Medical.
The equity round came from Ballast Point Ventures and River Cities Capital Funds, according to a press release.
Doral, Fla.-based TissueTech makes amniotic membrane- and umbilical cord-based products designed to treat ocular surface diseases (Bio-Tissue) and musculoskeletal conditions and wound care (Amniox Medical), according to the release.